Keira Driansky

Ensoma

Jim Burns

Ensoma has appointed Jim Burns as chief executive officer. Burns brings over two decades of experience working in a variety of senior position. He most recently served as chief executive officer at Locanabio. Prior to this, he served as president and chief executive officer of Casebia Therapeutics and also previously held multiple roles at Sanofi.

Kancera

Robert Edfors

Kancera has appointed Robert Edfors as chief scientific officer and senior vice president, clinical development. Edfors holds more than 15 years of experience from the pharmaceutical industry, academic research and as a clinician. He most recently served as global medical affairs physician at Bayer, which followed on from his position as medical advisor.

Valneva

Hanneke Schuitemaker

Valneva has appointed Hanneke Schuitemaker as chief scientific officer. Schuitemaker brings more than two decades of experience in vaccine discovery and development to her new role. She most recently served as global head, viral vaccine discovery and translational medicine at Johnson & Johnson. Prior to this, Schuitemaker held positions at Crucell Holland and Sanquin.

SynaptixBio

Uwe Meya

SynaptixBio has appointed Uwe Meya as chief medical officer. Meya brings almost four decades of experience to his new position. He has recently been serving as chief medical officer at GliaPharm. Prior to this, Meya served as chief medical officer at Minoryx Therapeutics. Earlier in his career, Meya held a variety of roles at Roche and Novartis.

Amarna Therapeutics

Aurelia Caparrós

Amarna Therapeutics has appointed Aurelia Caparrós as chief business officer. Caparrós brings over 25 years of healthcare industry experience to her new position. In her last role, she served as commercial head, oncology region Europe at Novartis, which followed on from her position as head of marketing and business excellence, oncology region Europe.

Kancera

Maria Sahlberg

Kancera has appointed Maria Sahlberg as vice president, regulatory affairs and compliance. Sahlberg brings more than 15 years of regional and global regulatory affairs experience to her new position. She most recently served as global regulatory affairs director at Inceptua group. Prior to this, Sahlberg served as senior global regulatory affairs manager at Sobi.

Seaport Therapeutics

Denice Torres

Seaport Therapeutics has appointed Denice Torres to its board of directors. Torres holds over three decades of experience in pharmaceuticals, consumer healthcare and medical devices. She held multiple positions at Johnson & Johnson, including president of J&J Consumer Healthcare and president of Janssen Neuroscience, and also previously held senior leadership roles at Eli Lilly.

Anocca

Christiane Hanke-Harloff

Anocca has appointed Christiane Hanke-Harloff to its board of directors. Hanke-Harloff brings a wealth of expertise and strategic insights to her latest position. She previously held executive roles at Gilead Sciences, Gedeon Richter and other biotech companies. She also currently serves as a board member of InnoCore Pharmaceuticals and Ascenion.